Premium
Omalizumab for the treatment of chronic inducible urticaria in 80 patients
Author(s) -
ExpositoSerrano V.,
CurtoBarredo L.,
Aguilera Peiro P.,
Gómez Armayones S.,
SerraBaldrich E.,
Spertino J.,
Bonfill Ortí M.,
Figueras Nart I.,
MeléNinot G.,
BaliuPiqué C.,
Sala Cunill A.,
LabradorHorrillo M.,
Guilabert Vidal A.,
Fernández Chico N.,
GiménezArnau A.M.
Publication year - 2021
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.19425
Subject(s) - omalizumab , medicine , chronic urticaria , dermatology , intensive care medicine , immunology , immunoglobulin e , antibody